Get access

Recent failures of new potential symptomatic treatments for parkinson's disease: Causes and solutions


  • Gurutz Linazasoro MD

    Corresponding author
    1. Centro de Neurología y Neurocirugía funcional, Clínica Quirón, San Sebastián, Guipúzcoa, Spain
    • Centro de Neurología y Neurocirugía funcional, Clínica Quirón, Parque Alcolea s/n, 20012 San Sebastián, Guipúzcoa, Spain
    Search for more papers by this author


One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management. The object of these new treatments should be to provide effective symptom control throughout the course of the disease without the development of side effects such as motor and psychiatric complications. Results of several clinical trials of new treatment options reported in the past 2 years have shown negative or unsatisfactory results. Most of the drugs and surgical procedures used in these studies had been tested previously in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys as well as in the classic 6-hydroxydopamine–lesioned rat model. They raise several questions about the true reliability of animal studies, the adequacy of the working hypotheses and design of clinical trials, the validity of tools in current use to evaluate a specific effect, and the selectivity of the drugs used. All these factors may explain failure. This review focuses on pharmacological and surgical treatments tested to improve the management of patients with motor fluctuations and dyskinesias. Some of the recent trials and possible reasons for their lack of success are critically analysed. Finally, some suggestions to avoid further failures and improve results are proposed. © 2004 Movement Disorder Society